Még nem toboroz
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
2024-517295-37-00· 3. fázis· University Of Cologne· Forrás
Toboroz
A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure
NCT07584967· 2. fázis· AnaCardio AB· Forrás
Toboroz
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.
2025-525030-57-00· 3. fázis· AstraZeneca AB· Forrás
Toboroz
Study QEL-005-CLN-01. Phase I/II study of QEL-005 in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).
2025-523971-46-00· 1/2. fázis· Quell Therapeutics Limited· Forrás
Még nem toboroz
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
2025-522190-11-01· 3. fázis· Universitaetsklinikum Schleswig-Holstein AöR· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
NCT07564141· 3. fázis· Genmab· Forrás
Még nem toboroz
Study of Zola-cel (BMS-986353), CD19 NEX-T CAR T Cells in Autoimmune Cytopenia (Breakfree-AiCE)
2025-524993-41-00· 2. fázis· Celgene Corp.· Forrás
Még nem toboroz
GMMG-HD11/DSMM XXI/64007957MMY3010
NCT07671287· 3. fázis· University of Heidelberg Medical Center· Forrás
Toboroz
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
NCT07387549· 3. fázis· Ipsen· Forrás
Toboroz
A Phase 3 Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children with Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
2025-523079-44-00· 3. fázis· Ascendis Pharma Endocrinology Division A/S· Forrás
Toboroz
Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants
2025-521762-99-00· 3. fázis· University Medical Center Hamburg-Eppendorf· Forrás
Toboroz
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281· 3. fázis· AstraZeneca· Forrás
Toboroz
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
2024-512503-39-00· 4. fázis· Medizinische Hochschule Hannover· Forrás
Toboroz
SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension
NCT06804161· 3. fázis· Prof. Dr. med. Ingo Eitel· Forrás
Toboroz
Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
NCT07038356· 3. fázis· Christian Schulze· Forrás
Toboroz
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· 3. fázis· Amgen· Forrás
Toboroz
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903· 3. fázis· Alnylam Pharmaceuticals· Forrás
Toboroz
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916· 3. fázis· Immunovant Sciences GmbH· Forrás
Toboroz
EURO-STIM Registry
NCT06971796· Inspire Medical Systems, Inc.· Forrás
Toboroz
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301· 2/3. fázis· Eikon Therapeutics· Forrás
Toboroz
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285· 3. fázis· Takeda· Forrás
Toboroz
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
NCT06890884· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479· 3. fázis· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Forrás
Fut, nem toboroz
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927· 3. fázis· Arcus Biosciences, Inc.· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647· 3. fázis· AstraZeneca· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738· 3. fázis· AstraZeneca· Forrás
Toboroz
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
MB-CART19.1 in refractory SLE
2023-507654-33-00· 1/2. fázis· Miltenyi Biomedicine GmbH· Forrás
Toboroz
MB-CART19.1 in Refractory SLE
NCT06189157· 1/2. fázis· Miltenyi Biomedicine GmbH· Forrás
Toboroz
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595· 3. fázis· AstraZeneca· Forrás
Toboroz
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial)
2023-507402-13-00· 3. fázis· Universitaetsklinikum Heidelberg AöR· Forrás
Fut, nem toboroz
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744· 3. fázis· Genmab· Forrás
Fut, nem toboroz
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491· 3. fázis· AstraZeneca· Forrás
Toboroz
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
NCT06061094· 2. fázis· Goethe University· Forrás
Fut, nem toboroz
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906· 3. fázis· Bayer· Forrás
Fut, nem toboroz
Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis
NCT03843385· 3. fázis· Andreas Stallmach· Forrás
Fut, nem toboroz
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT05409066· 3. fázis· Genmab· Forrás
Toboroz
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
NCT04628026· 3. fázis· University of Ulm· Forrás
Fut, nem toboroz
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842· 3. fázis· AstraZeneca· Forrás
Toboroz
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.
2024-510578-25-00· 3. fázis· The University Of Birmingham· Forrás
Fut, nem toboroz
Low-dose Atropine for Myopia Control in Children
NCT03865160· 2/3. fázis· University Eye Hospital, Freiburg· Forrás
Showing 50 of 68.